Field study of dried blood spot specimens for HIV-1 drug resistance genotyping

Journal of Clinical Microbiology

Volumn 52, Issue 8, 2014, Pages 2868-2875

  Parry, C M ^a,b   Parkin, N ^c   Diallo, K ^d   Mwebaza, S ^e   Batamwita, R ^e   DeVos, J ^d   Bbosa, N ^f   Lyagoba, F ^a   Magambo, B ^a   Jordan, M R ^g   Downing, R ^f   Zhang, G ^d   Kaleebu, P ^a   Yang, C ^d   Bertagnolio, S ^h  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c DATA FIRST CONSULTING INC   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e MILDMAY UGANDA   (Uganda)

^f CDC Uganda   (Uganda)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; EFAVIRENZ; EMTRICITABINE; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; ENVIRONMENTAL TEMPERATURE; FIELD STUDY; FREEZING; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; PLASMA; PRIORITY JOURNAL; SHIPPING; STORAGE TEMPERATURE; UGANDA; VENOUS BLOOD; VIRUS LOAD; BLOOD; DESICCATION; DRUG EFFECTS; EVALUATION STUDY; GENETICS; GENOTYPING TECHNIQUE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; MICROBIAL SENSITIVITY TEST; PROCEDURES; TEMPERATURE; UNITED STATES; VIROLOGY;

BLOOD; DESICCATION; DRUG RESISTANCE, VIRAL; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; SPECIMEN HANDLING; TEMPERATURE; UGANDA; UNITED STATES;

EID: 84905257992     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00544-14     Document Type: Article

References (41)

1. World Health Organization. 2013. Global update on HIV treatment 2013: results, impact and opportunities. World Health Organization. http://www.who.int/hiv/pub/progressreports/update2013/en/index.html. Accessed 24 September 2013.
2. Frentz D, Boucher CA, van de Vijver DA. 2012. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev. 14:17-27. http://www.aidsreviews.com/files/2012-14-1-017-027.pdf.
3. Stadeli KM, Richman DD. 2013. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir. Ther. 18:115-123. http://dx.doi.org/10.3851/IMP2437.
4. Sohn AH, Srikantiah P, Sungkanuparph S, Zhang F. 2013. Transmitted HIV drug resistance in Asia. Curr. Opin. HIV AIDS 8:27-33. http://dx.doi.org/10. 1097/COH.0b013e32835b804f.
5. Hamers RL, Sigaloff KC, Kityo C, Mugyenyi P, de Wit TF. 2013. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr. Opin. HIV AIDS 8:19-26. http://dx.doi.org/10.1097/COH. 0b013e32835b7f94.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2013. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/ guidelines. Accessed 5 December 2013.
7. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. 2008. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir. Ther. 13(Suppl 2):1-13. http://www.intmedpress.com/ serveFile.cfm?sUID=d7e0c91a-2622-4eff-acc3-b45f6e856a67. (Pubitemid 352019085)
8. World Health Organization. 2012. World Health Organization global strategy for the surveillance and monitoring of HIV drug resistance. World Health Organization. http://www.who.int/hiv/pub/drugresistance/drug-resistance- strategy/en/index.html. Accessed 14 February 2012.
9. Plantier JC, Dachraoui R, Lemee V, Gueudin M, Borsa-Lebas F, Caron F, Simon F. 2005. HIV-1 resistance genotyping on dried serum spots. AIDS 19:391-397. http://dx.doi.org/10.1097/01.aids.0000161768.98534.e7. (Pubitemid 40446185)
10. World Health Organization. 2013. Guidance on regulations for the Transport of Infectious Substances 2013-2014. World Health Organization. http://www.who.int/ihr/publications/who-hse-ihr-2012.12/en/. Accessed 9 May 2014.
11. Hamers RL, Smit PW, Stevens W, Schuurman R, Rinke de Wit TF. 2009. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir. Ther. 14:619-629. http://www.intmedpress.com/serveFile.cfm? sUID=8d7390e5-08b3-45ad-b56d-b7184f85d203.
12. Bertagnolio S, Parkin NT, Jordan M, Brooks J, Garcia-Lerma JG. 2010. Dried blood spots for HIV-1 drug resistance and viral load testing: a review of current knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS Rev. 12:195-208. http://www.aidsreviews.com/files/2010-12-4-195-208.pdf.
13. Buckton AJ. 2008. New methods for the surveillance of HIV drug resistance in the resource poor world. Curr. Opin. Infect. Dis. 21:653-658. http://dx.doi.org/10.1097/QCO.0b013e3283186d1a.
14. Buckton AJ, Bissett SL, Myers RE, Beddows S, Edwards S, Cane PA, Pillay D. 2008. Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. J. Antimicrob. Chemother. 62:1191-1198. http://dx.doi.org/10.1093/ jac/dkn412.
15. Zhou Z, Wagar N, DeVos JR, Rottinghaus E, Diallo K, Nguyen DB, Bassey O, Ugbena R, Wadonda-Kabondo N, McConnell MS, Zulu I, Chilima B, Nkengasong J, Yang C. 2011. Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings. PLoS One 6:e28184. http://dx.doi.org/10.1371/journal.pone.0028184.
16. Masciotra S, Garrido C, Youngpairoj AS, McNulty A, Zahonero N, Corral A, Heneine W, de Mendoza C, Garcia-Lerma JG. 2007. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 21:2503-2511. http://dx.doi.org/10. 1097/QAD.0b013e3281c618db. (Pubitemid 350145182)
17. Ziemniak C, Mengistu Y, Ruff A, Chen YH, Khaki L, Bedri A, Simen BB, Palumbo P, Eshleman SH, Persaud D. 2011. Use of dried-blood-spot samples and in-house assays to identify antiretroviral drug resistance in HIV-infected children in resource-constrained settings. J. Clin. Microbiol. 49:4077-4082. http://dx.doi.org/10.1128/JCM.01004-11.
18. Johannessen A, Garrido C, Zahonero N, Naman E, de Mendoza C. 2011. HIV-1 drug resistance testing from dried blood spots collected in rural Tanzania using the ViroSeq HIV-1 Genotyping System. J. Antimicrob. Chemother. 66:260-264. http://dx.doi.org/10.1093/jac/dkq433.
19. Monleau M, Butel C, Delaporte E, Boillot F, Peeters M. 2010. Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. J. Antimicrob. Chemother. 65:1562-1566. http://dx.doi.org/10.1093/jac/dkq205.
20. Hallack R, Doherty LE, Wethers JA, Parker MM. 2008. Evaluation of dried blood spot specimens for HIV-1 drug-resistance testing using the Trugene HIV-1 genotyping assay. J. Clin. Virol. 41:283-287. http://dx.doi.org/10.1016/j.jcv. 2007.12.011.
21. Youngpairoj AS, Masciotra S, Garrido C, Zahonero N, de Mendoza C, Garcia-Lerma JG. 2008. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4° C. J. Antimicrob. Chemother. 61:1217-1220. http://dx.doi.org/10.1093/jac/dkn100. (Pubitemid 351753584)
22. Parkin N, de Mendoza C, Schuurman R, Jennings C, Bremer J, Jordan MR, Bertagnolio S. 2012. Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network. Clin. Infect. Dis. 54(Suppl 4):S273-S279. http://dx.doi.org/10.1093/ cid/cir982.
23. Steegen K, Luchters S, Demecheleer E, Dauwe K, Mandaliya K, Jaoko W, Plum J, Temmerman M, Verhofstede C. 2007. Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots. J. Clin. Microbiol. 45:3342-3351. http://dx.doi.org/10. 1128/JCM.00814-07. (Pubitemid 47585660)
24. McNulty A, Jennings C, Bennett D, Fitzgibbon J, Bremer JW, Ussery M, Kalish ML, Heneine W, Garcia-Lerma JG. 2007. Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J. Clin. Microbiol. 45:517-521. http://dx.doi.org/10.1128/JCM.02016-06.
25. Rottinghaus EK, Ugbena R, Diallo K, Bassey O, Azeez A, Devos J, Zhang G, Aberle-Grasse J, Nkengasong J, Yang C. 2012. Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving firstline antiretroviral therapy. Clin. Infect. Dis. 54:1187-1195. http://dx.doi.org/10.1093/cid/cis015.
26. Bertagnolio S, Soto-Ramirez L, Pilon R, Rodriguez R, Viveros M, Fuentes L, Harrigan PR, Mo T, Sutherland D, Sandstrom P. 2007. HIV-1 drug resistance surveillance using dried whole blood spots. Antivir. Ther. 12:107-113. http://www.intmedpress.com/serveFile.cfm?sUID=c2e29fe6-5ce2-422a-b3e0- 40432e135435. (Pubitemid 46340432)
27. Hearps AC, Ryan CE, Morris LM, Plate MM, Greengrass V, Crowe SM. 2010. Stability of dried blood spots for HIV-1 drug resistance analysis. Curr. HIV Res. 8:134-140. http://dx.doi.org/10.2174/157016210790442740.
28. Ziemniak C, George-Agwu A, Moss WJ, Ray SC, Persaud D. 2006. A sensitive genotyping assay for detection of drug resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried blood spots or frozen RNA extracts. J. Virol. Methods 136:238-247. http://dx.doi.org/10. 1016/j.jviromet.2006.05.030. (Pubitemid 44051599)
29. García-Lerma JG, McNulty A, Jennings C, Huang D, Heneine W, Bremer JW. 2009. Rapid decline in the efficiency of HIV drug resistance genotyping from dried blood spots (DBS) and dried plasma spots (DPS) stored at 37 degrees C and high humidity. J. Antimicrob. Chemother. 64:33-36. http://dx.doi.org/10. 1093/jac/dkp150.
30. Monleau M, Montavon C, Laurent C, Segondy M, Montes B, Delaporte E, Boillot F, Peeters M. 2009. Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J. Clin. Microbiol. 47:1107-1118. http://dx.doi.org/10.1128/JCM.02255- 08.
31. Yang C, McNulty A, Diallo K, Zhang J, Titanji B, Kassim S, Wadonda-Kabondo N, Aberle-Grasse J, Kibuka T, Ndumbe PM, Vedapuri S, Zhou Z, Chilima B, Nkengasong JN. 2010. Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J. Clin. Microbiol. 48:3158-3164. http://dx.doi.org/10. 1128/JCM.00564-10.
32. Woods CK, Brumme CJ, Liu TF, Chui CK, Chu AL, Wynhoven B, Hall TA, Trevino C, Shafer RW, Harrigan PR. 2012. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J. Clin. Microbiol. 50:1936-1942. http://dx.doi.org/10.1128/JCM.06689-11.
33. Liu TF, Shafer RW. 2006. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin. Infect. Dis. 42:1608-1618. http://dx.doi.org/10.1086/503914.
34. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28:2731-2739. http://dx.doi.org/10.1093/molbev/msr121.
35. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57:289-300. http://www.jstor.org/stable/pdfplus/2346101.pdf.
36. Fajardo E, Metcalf CA, Chaillet P, Aleixo L, Pannus P, Panunzi I, Trivino L, Ellman T, Likaka A, Mwenda R. 2014. Prospective evaluation of diagnostic accuracy of dried blood spots from finger prick samples for determination of HIV-1 load with the NucliSENS Easy-Q HIV-1 version 2.0 assay in Malawi. J. Clin. Microbiol. 52:1343-1351. http://dx.doi.org/10.1128/JCM.03519-13.
37. Bruisten SM, Oudshoorn P, van Swieten P, Boeser-Nunnink B, van Aarle P, Tondreau SP, Cuypers HTM. 1997. Stability of HIV-1 RNA in blood during specimen handling and storage prior to amplification by NASBA-QT. J. Virol. 67:199-207. http://www.sciencedirect.com/science/article/pii/S0166093497000979. (Pubitemid 27373706)
38. Amellal B, Murphy R, Maiga A, Brucker G, Katlama C, Calvez V, Marcelin AG. 2008. Stability of HIV RNA in plasma specimens stored at different temperatures. HIV Med. 9:790-793. http://dx.doi.org/10.1111/j.1468-1293.2008. 00632.x.
39. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes ME, Mandaliya K, Wellington M, Osibogun A, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER). 2011. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J. Acquir. Immune Defic. Syndr. 58:23-31. http://dx.doi.org/10.1097/QAI.0b013e318227fc34.
40. Hirnschall G, Harries AD, Easterbrook PJ, Doherty MC, Ball A. 2013. The next generation of the World Health Organization's global antiretroviral guidance. J. Int. AIDS Soc. 16:18757. http://dx.doi.org/10.7448/IAS.16.1.18757.
41. World Health Organization. 2013. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. World Health Organization. http://apps.who.int/ iris/bitstream/10665/85321/1/9789241505727-eng.pdf. Accessed 23 September 2013.